FDA OKs Tesaro’s niraparib for ovarian cancer, handing the biotech a big win on the label
The FDA has wasted no time in giving Tesaro $TSRO a broad approval for the use of its PARP drug niraparib, which will now be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
